Dynavax Applied sciences Company (NASDAQ:DVAX) Q1 2025 Earnings Convention Name Could 6, 2025 4:30 PM ET

Firm Individuals

Paul Cox – Vice President, Investor Relations & Company Communications
Ryan Spencer – Chief Govt Officer
Donn Casale – Chief Industrial Officer
Rob Janssen – Chief Medical Officer
Kelly MacDonald – Chief Monetary Officer

Convention Name Individuals

Matt Phipps – William Blair
Roy Buchanan – Residents
Jonathan Miller – Evercore ISI
Phil Nadeau – TD Cowen

Operator

Good day women and gents and welcome to the Dynavax Applied sciences’ First Quarter 2025 Monetary Outcomes Convention Name. As a reminder, this name is being recorded. On the finish of the corporate’s ready remarks, we are going to open the decision for questions and supply particular participation directions at the moment.

I’d now like handy the decision over to Paul Cox, Vice President, Investor Relations and Company Communications. You might now start.

Paul Cox

Thanks for taking part in immediately’s name. Becoming a member of me from Dynavax are Ryan Spencer, Chief Govt Officer; Donn Casale, Chief Industrial Officer; Rob Janssen, Chief Medical Officer and Kelly MacDonald, our Chief Monetary Officer.

Earlier immediately, Dynavax launched monetary outcomes for the primary quarter ended March 31, 2025. Copies of the press launch and a supplementary slide presentation can be found on Dynavax’s web site.

Earlier than we start, I counsel you that we’ll be making forward-looking statements immediately based mostly on our present expectations and beliefs together with however not restricted to potential market sizes, market segmentation, efficient advertising efforts, future anticipated market share and associated progress charges and associated ACIP advice affect on every.

Monetary steerage and tendencies together with income, profitability, money circulation and sufficiency of present capitalization, timing and outcomes of FDA submissions, scientific trial begins and knowledge readouts, and potential future makes use of of or demand for our CpG-1018 adjuvant. These statements contain dangers and uncertainties and our precise